Xcube.bio invests capital, knowledge and capabilities in the European market entry of late-stage biopharmas, with the objective to create partners' own commercial footprint and revenue streams. We offer a unique value proposition that open and de-risk the European market for innovative therapies.
Cooperation possibilities
Xcube.bio sets up operations of commercial stage Biopharmas in Europe, delivering fully functioning organizations after a temporary partnership. Our distinctive approach mitigates the risks and costs of therapeutic launches, through combination of equity, expertise and enablers that optimises value.
Some insights
xcube.bio accelerate availability of therapeutic innovation to European patients with high-unmet needs. We deliver the "last mile" from the end of clinical program to the regular patient.
Flagship pioneering for their ability to repeatedly create companies with strong clinical innovation
we stand at the cross-road deep expertise and willingness to challenge the status-quo
Rich business environment, breath of competencies, all at hand.
Late stage innovative biopharma looking to get to commercial stage.